Discover our strategy

Stay Ahead with Ananda Scientific Updates

Subscribe to our newsletter for company updates!

Why Investors Choose Ananda Scientific

Multiple Near-Term Catalysts in 2025: Potential start to a Pivotal trial in PTSD, Phase II read out SAD
Two Well-Powered Phase II Randomized Controlled Trials for PTSD in progress
Patented Delivery Technology Platform, Unleashing the True Potential of CBD in Multiple Neuropsychiatric Indications
Superior Pharmacokinetic Performance when compared with FDA-Approved Competitors
Robust GMP Compliant Manufacturing and Supply Chain Infrastructure for Clinical Trials and Subsequent Commercialization

Ready to Learn More?

Join a growing base of investors who engage with Ananda Scientific!
Connect with our team or access our latest investor materials today.

Disclaimer

All investing is subject to risk, including the possible loss of the money you invest.

These statements should not be construed as, (i) an offer to sell or a solicitation of an offer to buy any security, or (ii) investment, tax, legal, or other advice. Any such offer or solicitation will be made only by means of an offering document that meets all applicable legal requirements.

Statements contained herein that are not historical facts, including statements regarding objectives, strategies, and performance targets, may constitute forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied in such statements. Past performance is not necessarily indicative of, and cannot be relied upon as a guarantee of, future results. Investors should consult their own advisors with respect to any investment decision.

Terms & Use